New R&D tax credit creates Australian "sweet spot" for start-ups and foreign firms
This article was originally published in Scrip
Australia's senate has today passed tax law reforms revamping the country's outmoded tax credit system. The new R&D Tax Credit will put start-up biotechs, especially those that make trading losses, in "the sweet spot", according to industry association AusBiotech.
You may also be interested in...
Pharmaceutical industry groups say the European Commission’s Pharmaceutical Strategy Roadmap lacks detail on delivering a faster regulatory process and encouraging competitiveness.
The Australian Therapeutic Goods Administration is consulting on a draft standard for data matrix codes on the labels of certain medicines.
The European Medicines Agency received more requests for scientific advice in 2019 than it did in 2018. Meanwhile, requests for advice in other areas has fallen.